Clinical trial
Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and…
NCT00481143 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00481143 |
|---|---|
| Title | Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload |
| Official title | A One-year, Open-label, Single Arm, Multi-center Trial Evaluating the Efficacy and Safety of Oral ICL670 in Patients Diagnosed With Low and INT-1 Risk Myelodysplastic Syndrome (MDS) and Transfusion-dependent Iron Overload |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes, Transfusion Dependent Iron Overload |
| Intervention type | Drug |
| Interventions | ICL670/Deferasirox |
| Enrollment | 63 |
| Start date | May 1, 2007 |
| Primary completion | Nov 1, 2010 |
| First posted | Jun 1, 2007 |
| Last update posted | May 31, 2017 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: